<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83715">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02015481</url>
  </required_header>
  <id_info>
    <org_study_id>BBCO-001</org_study_id>
    <nct_id>NCT02015481</nct_id>
  </id_info>
  <brief_title>Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients</brief_title>
  <acronym>HOPEMD</acronym>
  <official_title>Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in OPMD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioblast Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioblast Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous
      Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vital signs</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>safety lab tests</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in disease markers</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Oculopharyngeal Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Cabaletta 30gr.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly IV of Cabaletta 30gr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabaletta</intervention_name>
    <arm_group_label>Cabaletta 30gr.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  18 - 80 years (inclusive) of age

          -  Clinically and genetically diagnosed as OPMD

          -  Moderate dysphagia (abnormal drinking test at screening and on the first dosing day,
             before drug administration)

          -  Patients who provide written informed consent to participate in the study

          -  Body Mass Index (BMI) &lt;30 kg/m2

        Exclusion Criteria:

          -  Diabetes mellitus type 1 or 2

          -  Other major diseases, e.g.: renal failure (creatinine clearance &lt;60ml/min), liver
             failure and chronic liver diseases (e.g. hepatitis B or C) , HIV carriers,
             tuberculosis, SLE, rheumatoid polyarthritis, sarcoidosis, collagenosis

          -  Uncontrolled heart disease , CHF,

          -  Other neuromuscular diseases

          -  Other disorders associated with esophageal dysphagia: e.g. severe gastroesophageal
             reflux (GERD), esophageal stricture due to mechanical or chemical trauma, infection
             (e.g. esophageal moniliasis), drug-induced dysphagia (e.g. bisphosphonates),
             esophageal rings and webs, spastic motility disorders of the esophagus.

          -  History of malignancy (except non-invasive skin malignancy)

          -  History of neck irradiation

          -  Pregnant or currently lactating women

          -  Obesity (BMI≥ 30) and associated morbidity

          -  Prior pharyngeal myotomy

          -  Weight loss of more than 10% in the last 12 months.

          -  Known hypersensitivity to any ingredients in the injection

          -  Patient receiving anticoagulant treatment (e.g. warfarin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoseph Caraco, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Brais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Neurological Institute, McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tahseen Mozaffar</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute, McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah medical center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>April 5, 2016</lastchanged_date>
  <firstreceived_date>December 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Case control, safety, tolerability, efficacy.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Oculopharyngeal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
